|
Nov 6
|
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2023 Earnings Call Transcript
|
|
Nov 2
|
Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study Group 2023
|
|
Oct 26
|
Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
|
|
Oct 24
|
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
|
|
Sep 12
|
Can Neurocrine Erase Its Recent Setbacks With This Jump To An Eight-Month High?
|
|
Sep 12
|
Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)
|
|
Sep 11
|
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
|
|
Sep 11
|
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
|
|
Sep 6
|
Biden FTC’s Antitrust Bark Proves Worse Than Its Bite
|
|
Jul 18
|
Neurocrine Biosciences (NASDAQ:NBIX) shareholders have endured a 28% loss from investing in the stock three years ago
|